Company Overview
ResMed Inc. functions as a specialized developer, manufacturer, distributor, and marketer of medical devices and cloud-based software applications designed to diagnose, treat, and manage respiratory disorders across the United States and international markets. The company operates within the Healthcare sector, specifically serving the Medical Instruments & Supplies industry, a classification that underscores its focus on essential diagnostic and therapeutic equipment rather than general consumer goods or pharmaceuticals. As a significant entity in this space, ResMed commands a market capitalization of $32.18B and generates annual revenue reaching $5.40B, though the specific count of employees is not disclosed in the available data. These financial magnitudes indicate that the company holds a substantial position in the global respiratory care market, suggesting a high level of brand recognition and established distribution networks necessary to sustain such a large market cap relative to its revenue stream.
Financial Health
The company reports a Total Revenue of $5.40B over the trailing twelve months, with a corresponding Net Income of $1.49B and an EBITDA figure of $2.02B, highlighting a robust conversion of sales into bottom-line profit. The gap between the $5.40B revenue and the $1.49B net income reveals a highly efficient cost structure, where operating expenses and taxes consume only a fraction of top-line sales, a characteristic typical of high-margin medical device manufacturers. Free cash flow stands at $1.42B, a metric that aligns closely with the company's total cash balance of $1.42B, indicating strong operational liquidity and significant financial flexibility to fund capital expenditures or strategic acquisitions without immediate reliance on external financing. Profitability is further evidenced by three distinct margin levels: a Gross Margin of 61.5%, an Operating Margin of 35.2%, and a Profit Margin of 27.5%, all of which reflect the company's ability to maintain pricing power while controlling production and operational costs effectively. Regarding leverage, ResMed holds $1.42B in cash against $847.72M in debt, resulting in a Debt to Equity ratio of 13.41, which suggests a balance sheet that is heavily weighted toward cash assets rather than financial liabilities, presenting a conservative stance on net debt despite the high gross leverage ratio. Short-term liquidity is exceptionally strong with a Current Ratio of 3.06, indicating that the company possesses more than three times the liquid assets required to cover its short-term obligations, thereby minimizing the risk of insolvency in the near term. Finally, the Return on Equity is 25.7% and the Return on Assets is 14.7%, metrics that demonstrate management's effectiveness in generating significant returns from shareholder capital and utilizing the total asset base to drive profitability.
Valuation Assessment
The stock carries a Trailing Twelve Month P/E ratio of 21.79 and a Forward P/E of 18.10, and the divergence between these two figures implies that the market anticipates an acceleration in earnings growth that would justify a lower multiple on future expectations relative to current valuations. Valuation relative to tangible assets is indicated by a Price to Book ratio of 5.08, which suggests that the market assigns a significant premium to the company's intangible assets, such as its proprietary technology, brand value, and distribution infrastructure, far exceeding the value of its net book value. Alternative valuation metrics provide further context, with a Price to Sales ratio of 5.96 and an EV/EBITDA of 15.58, figures that suggest the market is willing to pay a high multiple for every dollar of sales and earnings, reflecting confidence in the durability of its revenue streams and cash generation capabilities. In terms of recent price action, the 52-week high is recorded at $293.81 and the 52-week low at $199.92, providing a clear range within which the stock has traded over the past year. The Beta value is 0.89, which indicates that the stock's price volatility is slightly lower than that of the broader market, suggesting that the stock tends to be less sensitive to general market fluctuations compared to the average large-cap stock.
Growth & Income
ResMed Inc. is currently experiencing Revenue Growth of 11.0% year-over-year and Earnings Growth of 14.5% year-over-year, demonstrating that earnings are expanding at a faster rate than revenue, which implies that the company is benefiting from operational leverage, pricing power, or margin expansion as it scales its operations. As a dividend payer, the company offers a Dividend Yield of 1.1% with a Payout Ratio of 22.4%, a payout ratio that is notably low and suggests that the dividend is highly sustainable given the company's strong earnings growth and robust free cash flow generation. This conservative payout strategy allows the firm to retain a substantial portion of its earnings for reinvestment into research and development or debt reduction rather than distributing maximum cash to shareholders. The overall growth and income profile combines double-digit revenue expansion with accelerating earnings growth and a modest, sustainable dividend yield, positioning the company as a compounder that balances income generation with capital appreciation potential in the healthcare sector.